

## Regimen Reference Order – GAST – nivolumab + CISplatin + fluorouracil

ARIA: GAST - [nivolumab + CIS + 5FU]

**Planned Course:** nivolumab + CISplatin + fluorouracil every 21 days until disease progression or unacceptable toxicity up to a maximum of 35 cycles (2 years)

**Indication for Use:** Gastric or Gastroesophageal Junction or Esophageal Adenocarcinoma; Locally Advanced/Metastatic

**Drug Alert:** Immune Checkpoint Inhibitor (nivolumab)

**CVAD:** Required (Ambulatory Pump)

### Proceed with treatment if:

- **ANC equal to or greater than  $1.5 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$**
  - **AST/ALT equal to or less than 3 times the upper limit of normal**
  - **Total bilirubin equal to or less than 1.5 times the upper limit of normal**
  - **Creatinine clearance is greater than 45 mL/minute**
- ❖ **Contact Physician if parameters not met**

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – GAST – nivolumab + CISplatin + fluorouracil

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
nivolumab	4.5 mg/kg	IV in normal saline 100 mL over 30 minutes <i>Use 0.2 or 0.22 micron filter</i>
magnesium sulfate	2 g	IV in normal saline 1000 mL over 2 hours (Pre hydration)
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
OLANzapine	2.5 mg	Orally 30 minutes pre-chemotherapy
CISplatin	80 mg/m <sup>2</sup>	IV in normal saline 500 mL over 1 hour <b>*Alert: CISplatin infusion must be complete prior to mannitol administration</b>
mannitol	12.5 g	IV in normal saline 1000 mL over 2 hours (Post hydration)

fluorouracil	4000 mg/m <sup>2</sup>	IV in D5W continuously over 96 hours by ambulatory infusion device
<b>Maximum nivolumab dose is 360 mg</b>		
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

### All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- TSH as per Physician Orders
- Baseline blood pressure prior to magnesium infusion and repeat 15 minutes after start of magnesium infusion
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after nivolumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

## Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
aprepitant	80 mg	Orally once daily on Days 2 and 3
dexamethasone	8 mg	Orally once daily on Days 2, 3 and 4
OLANzapine	2.5 mg	Orally the evening of Day 1 then twice daily on Days 2, 3 and 4. Also use OLANzapine 2.5 to 5 mg AS NEEDED for breakthrough nausea and vomiting (including Days 1 to 4) up to a maximum of 10 mg per day. Contact clinic if nausea/vomiting is not adequately controlled

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
  - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted
- Instruct patient to continue taking anti-emetic(s) at home
- Ensure patient has received a home chemotherapy spill kit and instructions for use
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

---

**ADDITIONAL INFORMATION**

---

- nivolumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated
- CISplatin is ototoxic and nephrotoxic
- CISplatin can cause hypomagnesemia